WHO Model List of Essential Medicines for Children

The WHO Model List of Essential Medicines for Children (aka Essential Medicines List for Children[1] or EMLc[1]), published by the World Health Organization (WHO), contains the medications considered to be most effective and safe in children up to twelve years of age to meet the most important needs in a health system.[2][3]

The list is divided into core items and complementary items.[4] The core items are deemed to be the most cost-effective options for key health problems and are usable with little additional health care resources.[4] The complementary items either require additional infrastructure such as specially trained health care providers or diagnostic equipment or have a lower cost–benefit ratio.[4]

The first list for children was created in 2007, and the list is in its 8th edition as of 2021.[5][4][6]

Note: An α indicates a medicine is on the complementary list.[4]

Anaesthetics, preoperative medicines and medical gases

edit

General anaesthetics and oxygen

edit

Inhalational medicines

edit

Injectable medicines

edit

Local anaesthetics

edit

Preoperative medication and sedation for short-term procedures

edit

Medical gases

edit

Medicines for pain and palliative care

edit

Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)

edit

Opioid analgesics

edit

Medicines for other symptoms common in palliative care

edit

Antiallergics and medicines used in anaphylaxis

edit

Antidotes and other substances used in poisonings

edit

Non-specific

edit

Specific

edit

Anticonvulsants/antiepileptics

edit

Anti-infective medicines

edit

Anthelminthics

edit

Intestinal anthelminthics

edit
 
A skeletal model of the chemical structure of albendazole

Antifilarials

edit

Antischistosomals and other antinematode medicines

edit

Cysticidal medicines

edit

Antibacterials

edit

Access group antibiotics

edit

Watch group antibiotics

edit

Reserve group antibiotics

edit

Reserve antibiotics are last-resort antibiotics. The EML antibiotic book was published in 2022.[7][8][9]

Antileprosy medicines

edit

Antituberculosis medicines

edit
 
Pure crystals of ethambutol

Antifungal medicines

edit

Antiviral medicines

edit

Antiherpes medicines

edit

Antiretrovirals

edit
Nucleoside/nucleotide reverse transcriptase inhibitors
edit
Non-nucleoside reverse transcriptase inhibitors
edit
Protease inhibitors
edit
Integrase inhibitors
edit
Fixed-dose combinations of antiretroviral medicines
edit
edit

Other antivirals

edit

Antihepatitis medicines

edit
Medicines for hepatitis B
edit
Nucleoside/Nucleotide reverse transcriptase inhibitors
edit
Medicines for hepatitis C
edit
Pangenotypic direct-acting antiviral combinations
edit
Non-pangenotypic direct-acting antiviral combinations
edit

No listings in this section.

Other antivirals for hepatitis C
edit

No listings in this section.

Antiprotozoal medicines

edit

Antiamoebic and antigiardiasis medicines

edit

Antileishmaniasis medicines

edit

Antimalarial medicines

edit
For curative treatment
edit
For chemoprevention
edit

Antipneumocystosis and antitoxoplasmosis medicines

edit

Antitrypanosomal medicines

edit
African trypanosomiasis
edit
1st stage
edit
2nd stage
edit
American trypanosomiasis
edit

Medicines for ectoparasitic infections

edit

Antimigraine medicines

edit

For treatment of acute attack

edit

For prophylaxis

edit

Immunomodulators and Antineoplastics

edit

Immunomodulators for non-malignant disease

edit

Antineoplastic and supportive medicines

edit

Cytotoxic medicines

edit

Targeted therapies

edit

Immunomodulators

edit

Hormones and antihormones

edit

Supportive medicines

edit

Medicines affecting the blood

edit

Antianaemia medicines

edit

Medicines affecting coagulation

edit

Other medicines for haemoglobinopathies

edit

Blood products of human origin and plasma substitutes

edit

Blood and blood components

edit
 
Bag containing one unit of fresh frozen plasma

Plasma-derived medicines

edit

Human immunoglobulins

edit

Blood coagulation factors

edit

Plasma substitutes

edit

Cardiovascular medicines

edit

Antianginal medicines

edit

No listings in this section.

Antiarrhythmic medicines

edit

No listings in this section.

Antihypertensive medicines

edit

Medicines used in heart failure

edit

Antithrombotic medicines

edit

No listings in this section.

Lipid-lowering agents

edit

No listings in this section.

Dermatological medicines (topical)

edit

Antifungal medicines

edit

Anti-infective medicines

edit

Anti-inflammatory and antipruritic medicines

edit

Medicines affecting skin differentiation and proliferation

edit

Scabicides and pediculicides

edit

Diagnostic agents

edit

Ophthalmic medicines

edit

Radiocontrast media

edit

Disinfectants and antiseptics

edit

Antiseptics

edit

Disinfectants

edit

Diuretics

edit

Gastrointestinal medicines

edit

Antiulcer medicines

edit

Antiemetic medicines

edit

Anti-inflammatory medicines

edit

No listings in this section.

Laxatives

edit

No listings in this section.

Medicines used in diarrhoea

edit

Oral rehydration

edit

Medicines for diarrhoea

edit

Medicines for endocrine disorders

edit

Adrenal hormones and synthetic substitutes

edit

Androgens

edit

No listings in this section.

Estrogens

edit

No listings in this section.

Progestogens

edit

No listings in this section.

Medicines for diabetes

edit

Insulins

edit

Oral hypoglycaemic agents

edit

Medicines for hypoglycaemia

edit

Thyroid hormones and antithyroid medicines

edit

Immunologicals

edit

Diagnostic agents

edit

Sera and immunoglobulins

edit

Vaccines

edit

Recommendations for all

Recommendations for certain regions

Recommendations for some high-risk populations

Recommendations for immunization programmes with certain characteristics

Muscle relaxants (peripherally-acting) and cholinesterase inhibitors

edit

Ophthalmological preparations

edit

Anti-infective agents

edit

Anti-inflammatory agents

edit

Local anaesthetics

edit

Miotics and antiglaucoma medicines

edit

No listings in this section.

Mydriatics

edit

Anti-vascular endothelial growth factor (VEGF) preparations

edit

No listings in this section.

Medicines for reproductive health and perinatal care

edit

Contraceptives

edit

No listings in this section.

Ovulation inducers

edit

No listings in this section.

Uterotonics

edit

No listings in this section.

Antioxytocics (tocolytics)

edit

No listings in this section.

Other medicines administered to the mother

edit

No listings in this section.

Medicines administered to the neonate

edit

Peritoneal dialysis solution

edit

Medicines for mental and behavioural disorders

edit

Medicines used in psychotic disorders

edit

Medicines used in mood disorders

edit

Medicines used in depressive disorders

edit

Medicines used in bipolar disorders

edit

No listings in this section.

Medicines for anxiety disorders

edit

No listings in this section.

Medicines used for obsessive compulsive disorders

edit

No listings in this section.

Medicines for disorders due to psychoactive substance use

edit

No listings in this section.

Medicines acting on the respiratory tract

edit

Antiasthmatic medicines

edit

Solutions correcting water, electrolyte and acid-base disturbances

edit

Oral

edit

Parenteral

edit

Miscellaneous

edit

Vitamins and minerals

edit

Ear, nose and throat medicines

edit

Medicines for diseases of joints

edit

Medicines used to treat gout

edit

No listings in this section.

Disease-modifying agents used in rheumatoid disorders

edit

Juvenile joint diseases

edit

Dental preparations

edit

Notes

edit
  1. ^ Thiopental may be used as an alternative depending on local availability and cost.
  2. ^ No more than 30% oxygen should be used to initiate resuscitation of neonates less than or equal to 32 weeks of gestation.
  3. ^ Not in children less than three months.
  4. ^ Not recommended for anti‐inflammatory use due to lack of proven benefit to that effect.
  5. ^ Alternatives limited to hydromorphone and oxycodone.
  6. ^ For the management of cancer pain.
  7. ^ a b Alternatives limited to dolasetron, granisetron, palonosetron, and tropisetron
  8. ^ Alternatives limited to cetirizine and fexofenadine
  9. ^ There may be a role for sedating antihistamines for limited indications.
  10. ^ Alternatives limited to prednisone
  11. ^ For use as adjunctive therapy for treatment-resistant partial or generalized seizures.
  12. ^ Alternatives limited to diazepam and midazolam
  13. ^ For buccal administration when solution for oromucosal administration is not available.
  14. ^ The presence of both 25 mg/5 mL and 30 mg/5 mL strengths on the same market would cause confusion in prescribing and dispensing and should be avoided.
  15. ^ a b Avoid use in pregnancy and in women and girls of child-bearing potential, unless alternative treatments are ineffective or not tolerated because of the high risk of birth defects and developmental disorders in children exposed to valproate in the womb.
  16. ^ Oxamniquine is listed for use when praziquantel treatment fails.
  17. ^ > 1 month.
  18. ^ Only for the presumptive treatment of epidemic meningitis in children older than two years and in adults.
  19. ^ Alternatives limited to 4th level ATC chemical subgroup (J01CF Beta-lactamase resistant penicillins)
  20. ^ cloxacillin, dicloxacillin and flucloxacillin are preferred for oral administration due to better bioavailability.
  21. ^ Use in children <8 years only for life-threatening infections when no alternative exists.
  22. ^ Procaine benzylpenicillin is not recommended as first-line treatment for neonatal sepsis except in settings with high neonatal mortality, when given by trained health workers in cases where hospital care is not achievable.
  23. ^ Third-generation cephalosporin of choice for use in hospitalized neonates.
  24. ^ Do not administer with calcium and avoid in infants with hyperbilirubinemia.
  25. ^ > 41 weeks corrected gestational age.
  26. ^ Erythromycin may be an alternative.
  27. ^ Imipenem/cilastatin is an alternative for complicated intraabdominal infections and high-risk febrile neutropenia only, except for acute bacterial meningitis in neonates, where meropenem is preferred
  28. ^ For use only in combination with meropenem.
  29. ^ Terizidone may be an alternative
  30. ^ Prothionamide may be used as an alternative.
  31. ^ For treatment of chronic pulmonary aspergillosis, acute invasive aspergillosis, histoplasmosis, sporotrichosis, paracoccidiodomycosis, mycoses caused by T. marneffei and chromoblastomycosis; and prophylaxis of histoplasmosis and infections caused by T. marneffei in AIDS patients.
  32. ^ For treatment of chronic pulmonary aspergillosis and acute invasive aspergillosis.
  33. ^ Alternatives limited to anidulafungin and caspofungin
  34. ^ for use in second-line regimens in accordance with WHO treatment guidelines
  35. ^ For the treatment of viral haemorrhagic fevers only.
  36. ^ Severe illness due to confirmed or suspected influenza virus infection in critically ill hospitalized patients
  37. ^ For the treatment of cytomegalovirus retinitis (CMVr).
  38. ^ Pangenotypic when used in combination with sofosbuvir
  39. ^ Pangenotypic when used in combination with daclatasvir
  40. ^ Alternatives limited to tinidazole
  41. ^ To be used in combination with artesunate 50 mg.
  42. ^ For use in the management of severe malaria.
  43. ^ Not recommended in the first trimester of pregnancy or in children below 5 kg.
  44. ^ To be used in combination with either amodiaquine, mefloquine or sulfadoxine + pyrimethamine.
  45. ^ Other combinations that deliver the target doses required such as 153 mg or 200 mg (as hydrochloride) with 50 mg artesunate can be alternatives.
  46. ^ For use only for the treatment of Plasmodium vivax infection.
  47. ^ For use only in combination with quinine.
  48. ^ To be used in combination with artesunate 50 mg.
  49. ^ Only for use to achieve radical cure of Plasmodium vivax and Plasmodium ovale infections, given for 14 days.
  50. ^ For use only in the management of severe malaria, and should be used in combination with doxycycline.
  51. ^ Only in combination with artesunate 50 mg.
  52. ^ For use only for the treatment of Plasmodium vivax infection.
  53. ^ For use only in combination with chloroquine.
  54. ^ For the treatment of 1st and 2nd stage of human African trypanosomiasis due to Trypanosoma brucei gambiense infection.
  55. ^ To be used for the treatment of Trypanosoma brucei gambiense infection.
  56. ^ To be used for the treatment of the initial phase of Trypanosoma brucei rhodesiense infection.
  57. ^ To be used for the treatment of Trypanosoma brucei gambiense infection
  58. ^ Only to be used in combination with eflornithine, for the treatment of Trypanosoma brucei gambiense infection.
  59. ^ etanercept and infliximab are alternatives, including quality-assured biosimilars
  60. ^ a b c d e f including quality-assured biosimilars
  61. ^ including quality-assured biosimilars
  62. ^ Alternatives limited to prednisone
  63. ^ Alternatives limited to epoetin alfa, beta and theta, darbepoetin alfa, and their quality-assured biosimilars.
  64. ^ Alternatives are limited to nadroparin, dalteparin, and their quality-assured biosimilars.
  65. ^ Alternatives are limited to the oral form of deferasirox.
  66. ^ Polygeline, injectable solution, 3.5% is considered as equivalent.
  67. ^ Alternatives limited to 4th level ATC chemical subgroup (C09AA ACE inhibitors, plain)
  68. ^ Alternatives limited to 4th level ATC chemical subgroup (D01AC Imidazole and triazole derivatives) excluding combinations
  69. ^ Alternatives limited to 4th level ATC chemical subgroup (D07AC Corticosteroids, potent (group III))
  70. ^ Alternatives limited to calcitriol and tacalcitol
  71. ^ Alternatives limited to podophyllotoxin
  72. ^ Alternatives limited to precipitated sulfur topical ointment
  73. ^ Alternatives limited to atropine and cyclopentolate
  74. ^ Alternatives limited to propanol
  75. ^ Alternatives limited to iodine
  76. ^ Alternatives limited to 4th level ATC chemical subgroup (D08AE Phenol and derivatives)
  77. ^ Alternatives limited to chlorothiazide and chlorthalidone
  78. ^ Alternatives limited to 4th level ATC chemical subgroup (A02BC Proton pump inhibitors) excluding combinations
  79. ^ Alternatives limited to 4th level ATC chemical subgroup (A02BA H2-receptor antagonists) excluding combinations
  80. ^ In acute diarrhoea zinc sulfate should be used as an adjunct to oral rehydration salts
  81. ^ Alternatives limited to insulin detemir, insulin degludec, and insulin glargine, including quality-assured biosimilars
  82. ^ Carbimazole is an alternative depending on local availability.
  83. ^ For use when alternative first-line treatment is not appropriate or available
  84. ^ Exact type to be defined locally.
  85. ^ a b c Recommended for certain regions
  86. ^ a b c d e f Recommended for some high-risk populations
  87. ^ a b c Recommended for immunisation programmes with certain characteristics
  88. ^ Infections due to Chlamydia trachomatis or Neisseria gonorrhoeae.
  89. ^ Alternatives limited to amikacin, kanamycin, netilmicin, and tobramycin
  90. ^ Alternatives limited to 4th level ATC chemical subgroup (S01AE Fluoroquinolones)
  91. ^ Alternatives limited to chlortetracycline and oxytetracycline
  92. ^ Alternatives limited to 4th level ATC chemical subgroup (S01HA Local anaesthetics) excluding cocaine and combinations
  93. ^ Alternatives limited to homatropine hydrobromide or cyclopentolate hydrochloride.
  94. ^ Alternatives limited to indometacin
  95. ^ Alternatives limited to prostaglandin E2
  96. ^ Alternatives limited to beclometasone, ciclesonide, flunisolide, fluticasone, and mometasone
  97. ^ Alternatives limited to terbutaline
  98. ^ Ergocalciferol can be used as an alternative.
  99. ^ Alternatives limited to ofloxacin
  100. ^ For use for rheumatic fever, juvenile arthritis, Kawasaki disease

References

edit
  1. ^ a b "WHO Model Lists of Essential Medicines". World Health Organization. Retrieved 15 April 2021.
  2. ^ "Essential medicines". World Health Organization. Archived from the original on 2 October 2008. Retrieved 20 January 2017.
  3. ^ World Health Organization (2021). The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2021 (including the 22nd WHO model list of essential medicines and the 8th WHO model list of essential medicines for children). Geneva: World Health Organization. hdl:10665/351172. ISBN 9789240041141. WHO technical report series;1035. License: CC BY-NC-SA 3.0 IGO.
  4. ^ a b c d e World Health Organization (2019). World Health Organization model list of essential medicines for children: 7th list 2019. Geneva. hdl:10665/325772. WHO/MVP/EMP/IAU/2019.07. License: CC BY-NC-SA 3.0 IGO.{{cite book}}: CS1 maint: location missing publisher (link)
  5. ^ World Health Organization (2021). World Health Organization model list of essential medicines for children: 8th list (2021). Geneva: World Health Organization. hdl:10665/345534. WHO/MHP/HPS/EML/2021.03.
  6. ^ World Health Organization (2019). Executive summary: the selection and use of essential medicines 2019: report of the 22nd WHO Expert Committee on the selection and use of essential medicines. Geneva. hdl:10665/325773. WHO/MVP/EMP/IAU/2019.05. License: CC BY-NC-SA 3.0 IGO.{{cite book}}: CS1 maint: location missing publisher (link)
  7. ^ "The WHO Essential Medicines List Antibiotic Book". World Health Organization (WHO). 24 November 2021. Retrieved 6 October 2022.
  8. ^ The WHO AWaRe (Access, Watch, Reserve) antibiotic book. Geneva: World Health Organization (WHO). 2022. ISBN 978-92-4-006238-2. Retrieved 29 January 2023.
  9. ^ The WHO AWaRe (Access, Watch, Reserve) antibiotic book - Infographics. Geneva: World Health Organization (WHO). 2022. WHO/MHP/HPS/EML/2022.02. Retrieved 29 January 2023.

Further reading

edit
  • World Health Organization (2015). The selection and use of essential medicines. Twentieth report of the WHO Expert Committee 2015 (including 19th WHO Model List of Essential Medicines and 5th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization. hdl:10665/189763. ISBN 9789240694941. ISSN 0512-3054. WHO technical report series; no. 994.
  • World Health Organization (2017). The selection and use of essential medicines: report of the WHO Expert Committee, 2017 (including the 20th WHO Model List of Essential Medicines and the 6th Model List of Essential Medicines for Children). Geneva: World Health Organization. hdl:10665/259481. ISBN 978-92-4-121015-7. ISSN 0512-3054. WHO technical report series; no. 1006.
  • World Health Organization (2019). The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2019 (including the 21st WHO Model List of Essential Medicines and the 7th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization. hdl:10665/330668. ISBN 9789241210300. ISSN 0512-3054. WHO technical report series;1021.
edit

eEML - Electronic Essential Medicines List